Indiplon in the treatment of sleep disorders

Review

(2709) Views  (380) Full article downloads

Author: Alan Lankford

Published Date January 2007 Volume 2007:3(6) Pages 765 - 773

DOI: http://dx.doi.org/10.2147/NDT.S494

Alan Lankford

Sleep Disorders Center of Georgia, Atlanta, GA, USA

Abstract: Indiplon is a novel sedative-hypnotic recently approved for the treatment of insomnia. Like other non-benzodiazepine hypnotics, its mechanism of action is to modulate subunits, especially the alpha-1 subunit, of the GABA receptor complex in order to induce sedation. Indiplon was developed in two different formulations to address two different types of insomnia complaint: indiplon-IR (immediate release) was designed for sleep onset difficulties, while indiplon-MR (modified release) was developed for sleep maintenance insomnia. While there are currently few peer reviewed articles about indiplon clinical trial results, the early information that is available seems to indicate that both formulations have been well tolerated and have proven effective at improving both patient reported and objectively measured sleep parameters in both adult and elderly insomnia patients. In May 2006, the FDA indicated that indiplon-IR was approvable and plans are to resubmit the application in 2007. Indiplon-MR was unapprovable and may require further evaluation.

Keywords: indiplon, insomnia, GABAA receptor, sedative, non-benzodiazepine